Allogene Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.20 Insider Own0.60% Shs Outstand143.66M Perf Week20.92%
Market Cap1.13B Forward P/E- EPS next Y-2.74 Insider Trans-4.53% Shs Float82.54M Perf Month40.93%
Income-312.70M PEG- EPS next Q-0.70 Inst Own76.20% Short Float / Ratio41.38% / 17.43 Perf Quarter-24.21%
Sales0.20M P/S5646.17 EPS this Y9.00% Inst Trans6.07% Short Interest34.16M Perf Half Y-40.23%
Book/sh5.15 P/B1.54 EPS next Y-15.60% ROA-32.60% Target Price22.69 Perf Year-29.41%
Cash/sh3.87 P/C2.04 EPS next 5Y1.00% ROE-37.70% 52W Range5.41 - 17.49 Perf YTD25.91%
Dividend- P/FCF- EPS past 5Y- ROI-27.90% 52W High-54.72% Beta0.76
Dividend %- Quick Ratio11.60 Sales past 5Y- Gross Margin- 52W Low46.53% ATR0.59
Employees356 Current Ratio11.60 Sales Q/Q0.00% Oper. Margin- RSI (14)61.18 Volatility10.01% 8.55%
OptionableYes Debt/Eq0.00 EPS Q/Q-1.40% Profit Margin- Rel Volume1.01 Prev Close7.83
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout- Avg Volume1.96M Price7.92
Recom1.90 SMA2020.84% SMA501.36% SMA200-23.11% Volume1,976,830 Change1.15%
Jan-24-23Upgrade JP Morgan Neutral → Overweight $20 → $11
Jan-06-23Upgrade Robert W. Baird Neutral → Outperform $12
Dec-12-22Downgrade BofA Securities Buy → Underperform $24 → $9
Aug-10-22Downgrade Raymond James Outperform → Mkt Perform
Jul-15-22Upgrade Goldman Neutral → Buy $9 → $32
Jun-03-22Initiated Robert W. Baird Neutral $11
Feb-28-22Reiterated B. Riley Securities Buy $30 → $21
Oct-20-21Initiated Cowen Outperform
Oct-08-21Downgrade Stifel Buy → Hold $44 → $18
Oct-08-21Downgrade Goldman Buy → Neutral $71 → $20
Show Previous Ratings
Jan-25-23 08:30AM
Jan-24-23 08:30AM
Jan-20-23 01:00PM
Jan-19-23 09:40AM
10:38AM Loading…
Jan-18-23 10:38AM
Jan-17-23 04:05PM
Jan-16-23 10:25AM
Jan-12-23 09:56AM
Jan-11-23 07:14PM
Jan-10-23 12:06PM
Jan-06-23 01:50PM
Jan-04-23 08:30AM
08:00AM Loading…
Jan-03-23 08:00AM
Dec-29-22 09:35AM
Dec-28-22 12:32PM
Dec-08-22 09:55AM
Dec-02-22 11:31AM
Nov-29-22 03:30PM
Nov-28-22 05:19AM
Nov-22-22 09:55AM
Nov-17-22 06:18PM
Nov-10-22 09:00AM
Nov-09-22 08:30AM
Nov-03-22 01:16PM
Nov-02-22 05:25PM
08:30AM Loading…
Oct-31-22 08:30AM
Oct-27-22 10:03AM
Oct-26-22 08:30AM
Oct-14-22 09:49AM
Oct-11-22 08:30AM
Oct-07-22 10:01AM
Oct-06-22 04:15PM
Sep-23-22 08:30AM
Sep-08-22 11:30AM
Aug-12-22 07:12AM
Aug-10-22 02:54PM
Aug-09-22 05:25PM
Aug-03-22 10:40AM
Jul-27-22 08:30AM
Jul-25-22 09:07AM
Jul-24-22 05:04AM
Jul-12-22 08:30AM
Jun-20-22 03:59PM
Jun-08-22 08:30AM
Jun-03-22 11:32AM
May-19-22 08:30AM
May-09-22 08:30AM
May-05-22 02:46PM
May-04-22 05:15PM
Apr-28-22 08:30AM
Apr-27-22 08:30AM
Apr-14-22 06:00PM
Apr-13-22 09:00AM
Apr-12-22 08:30AM
Mar-25-22 11:30AM
Mar-23-22 10:12AM
Mar-21-22 08:10AM
Mar-18-22 09:15AM
Mar-16-22 09:21AM
Mar-15-22 06:17AM
Mar-11-22 11:27AM
Mar-10-22 08:30AM
Mar-01-22 08:30AM
Feb-24-22 10:37AM
Feb-23-22 04:02PM
Feb-16-22 08:30AM
Feb-08-22 02:38PM
Feb-04-22 05:38PM
Feb-01-22 09:38PM
Jan-31-22 05:38PM
Jan-26-22 08:30AM
Jan-21-22 09:10AM
Jan-14-22 11:23AM
Jan-12-22 11:09AM
Jan-11-22 11:11AM
Jan-10-22 04:30PM
Jan-04-22 08:30AM
Dec-15-21 08:30AM
Dec-13-21 11:00AM
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bhavnagri VeerGeneral CounselJan 17Sale7.043,00021,120580,677Jan 18 06:10 PM
Bhavnagri VeerGeneral CounselDec 15Sale7.535,60242,186583,677Dec 19 04:29 PM
WITTE OWEN N.DirectorAug 12Sale17.255,00086,250218,271Aug 15 05:40 PM
WITTE OWEN N.DirectorAug 12Sale17.255,00086,250218,271Aug 15 05:12 PM
WITTE OWEN N.DirectorAug 11Sale16.5010,000165,000223,271Aug 15 05:12 PM
WITTE OWEN N.DirectorAug 11Sale16.5010,000165,000223,271Aug 15 05:40 PM
Amado RafaelEVP of R&D and CMOAug 02Sale11.972,00023,940540,257Aug 02 05:40 PM
Amado RafaelEVP of R&D and CMOJul 05Sale11.442,00022,880542,257Jul 06 04:16 PM
WITTE OWEN N.DirectorJun 22Sale11.7610,000117,600233,271Jun 23 04:40 PM
Amado RafaelEVP of R&D and CMOJun 21Sale11.182,00022,360544,257Jun 22 04:47 PM
Amado RafaelEVP of R&D and CMOMay 19Sale7.4011,50085,092546,257May 19 05:40 PM
Amado RafaelEVP of R&D and CMOMar 15Sale7.715,16939,848320,119Mar 17 05:59 PM
MOORE ALISONChief Technical OfficerMar 15Sale7.638,69866,388120,430Mar 17 05:58 PM
SCHMIDT ERIC THOMASChief Financial OfficerMar 15Sale7.6311,46987,551100,546Mar 17 05:58 PM
Chang David DPresident and CEOMar 15Sale7.6523,648180,8792,289,652Mar 17 05:59 PM
Bhavnagri VeerGeneral CounselMar 15Sale7.688,84967,962413,841Mar 17 05:59 PM